Japan To Survey Health Workers For H1N1 Vaccine Side Effects
This article was originally published in PharmAsia News
Japan's health ministry plans to ask a portion of the nation's million medical workers to document side effects from being vaccinated against the H1N1 influenza set to begin next week
You may also be interested in...
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.
New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.